4 December 2024
IXICO PLC
("IXICO" or the "Company")
Share Option Award & Director Bed & ISA Dealings
PDMR Dealing
Share Option Award:
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neurosciences, today announces that it has issued a total of 500,000 options to subscribe for ordinary shares of 1 pence each in the Company (the "Share Options") to Robin Wolz, CSO and a PDMR of the Company.
In recognition of his increasing contribution to the continued success of the Group, the Board has decided to provide Mr Wolz with share option performance criteria that is aligned with the Group's Executive Directors.
The Share Options have vesting criteria aligned with retention and annual share price growth over 3 years. These options have an exercise price of £0.01 and will be subject to a hold period to the third anniversary of their award.
The achievement of share price growth each year shall be measured by calculating the 3-month average share price immediately prior to each anniversary of the option award. The growth performance can be met in full by an absolute compound share price growth of 40% over the three-year period or in part by a 40% share price growth as compared to the prior year. In the first year this shall be compared to a baseline price equivalent to the three-month average share price immediately prior to the CEO joining the Company on 19 August 2024.
It is further announced that 200,000 options awarded to Mr Wolz on 30 October 2024 lapsed in full with effect from 28 November 2024.
Director Bed & ISA Dealings:
In addition, the Company announces that it received notification on 4 December 2024, that Grant Nash, CFO and PDMR, sold 260,000 ordinary shares of 1p each in the Company and repurchased 260,000 ordinary shares into Mr Nash's ISA account. Following this transaction Mr Nash's beneficial interest in the Company's shares has not changed.
The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.
For further information please contact:
| IXICO plc | +44 (0) 20 3763 7499 |
| Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer |
|
|
|
|
| Cavendish Capital Markets Limited (Nominated adviser and sole broker) | +44 (0) 20 7220 0500 |
| Giles Balleny / Dan Hodkinson (Corporate Finance) | |
| Nigel Birks (Life Sciences Specialist Sales) | |
| Harriet Ward (Corporate Broking) | |
| Michael F Johnson / Tamar Cranford Smith (Sales) | |
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on X (formerly Twitter) @IXICOnews
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Robin Wolz | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Chief Scientific Officer and PDMR | |||
| b)
| Initial notification /Amendment
| Initial | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| IXICO plc | |||
| b)
| LEI
| 2138005M1F59O6HWSA97 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Options over ordinary shares in IXICO plc
| |||
|
|
| ||||
| Identification code | ISIN: GB00BFXR4C20 | ||||
|
|
| ||||
| b)
| Nature of the transaction
| Grant of Share Options | |||
| c)
| Price(s) and volume(s) |
|
|
|
|
|
|
| Price(s) | Volume(s) |
| |
|
|
| 1 pence | 500,000 |
| |
|
|
|
|
|
| |
| d)
| Aggregated information |
| |||
|
|
| ||||
| - Aggregated volume | | ||||
|
|
| ||||
| - Price | | ||||
|
|
| ||||
| e)
| Date of the transaction
| 4 December 2024 | |||
| f)
| Place of the transaction
| Off Market Transaction | |||
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Grant Nash | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Chief Financial Officer and PDMR | |||
| b)
| Initial notification /Amendment
| Initial | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| IXICO plc | |||
| b)
| LEI
| 2138005M1F59O6HWSA97 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Ordinary shares in IXICO plc
| |||
|
|
| ||||
| Identification code | ISIN: GB00BFXR4C20 | ||||
|
|
| ||||
| b)
| Nature of the transaction
| Sale and purchase of ordinary shares | |||
| c)
| Price(s) and volume(s) |
|
|
|
|
|
|
| Price(s) | Volume(s) |
| |
|
|
| Sale at 12.000p | 260,000 |
| |
| | | Purchase at 12.015p | 260,000 | | |
|
|
|
|
|
| |
| d)
| Aggregated information |
| |||
|
|
| ||||
| - Aggregated volume | | ||||
|
|
| ||||
| - Price | | ||||
|
|
| ||||
| e)
| Date of the transaction | 4 December 2024 | |||
| f) | Place of the transaction
| Off Market Transaction | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
